HeartReady™ — a living cellular therapy, delivered into post-MI scar.
We grow mature, manufacturable human cardiomyocytes designed to engraft and restore function in post‑MI scar. Clinical translation and manufacturing readiness are core to the program.
In Development UnderCardia Therapeutics
The problem
The heart never heals itself.
Dead muscle becomes scar — stiff, silent, permanent.
The unmet need: post-MI scar & ischemic heart failure.
805K
Americans suffer a heart attack each year.
~90%
survive it. Modern cardiology is winning the first battle.
605K
Americans suffer their first MI each year.
50%
dead within five years — not waiting for another drug, but for new muscle.
The moat
The process is the product.
One iPSC becomes a mature ventricular cardiomyocyte: strong cardiac markers, adult-grade
electrophysiology, oxidative metabolism. Anyone can grow a cell. The defensible asset is
the route — the media, the timing, and the manufacturing — that does it reproducibly, at scale.
01
Proprietary differentiation
The signaling cocktail — growth factors, small molecules, timing — that drives a stem cell into a beating ventricular cardiomyocyte.
Methods · Media
02
Maturation protocol: EMM 2/1
The follow-up step that takes immature cells to adult-grade electrophysiology — the safety unlock for the field.
The safety unlock
03
Method of manufacturing
3D suspension bioreactor process with minimal batch-to-batch variability, end-to-end process analytics, and advanced cryopreservation.
3L → 15L scale
Patented8 patent filings· methods · media · process · AI/ML
BioEngineAI™
The operating system for biological intelligence.
The platform turns CardioVive data into actionable insight. BioEngineAI ingests imaging, motion,
sequencing, electrophysiology and bioprocess telemetry into a unified, queryable model.
01 · Inputs
Live-cell imaging
Motion / contractility
scRNA-seq
MEA / electrophysiology
Bioprocess telemetry
→
02 · Core
BioEngineAI™
A unified embedding space across modalities, donors, and time. NVIDIA Inception · AWS.
→
03 · Application heads
CytoVision™ · imaging
CytoMotion™ · contractility
CytoRNA™ · scRNA-seq
CytoGPT™ · semantic
→
04 · Twin
CytoTWIN™
Patient-specific digital twins — simulate response before the first dose. A future premium module built on the same biological data stack.
Tissue alone is not the moat. The edge is the AI layer that turns biology into structured, queryable data —
and the twin layer that lets partners simulate clinical response before dosing.
The wedge · flagship
CardioVive™: a beating heart model.
Our first commercial tissue wedge: iPSC-derived cardiac assembloids with functional chambers,
electrical activity, and resident immune cells — predictive of human pharmacology where
animal models fail. CardioVive is the data engine that powers BioEngineAI analytics.
Live CardioVive motion-vector and beating-velocity readout
Scientifically de-risked
The science already works — and ours is peer-reviewed.
The cell-therapy field is independently validated by the world's leading cardiac labs. Our own platform
doesn't rest on a pitch — it rests on peer-reviewed publications underpinning every layer of the stack.
CardioPhage™ biology — TRMPs integrate via Cx43 gap junctions, persist 60+ days, and improve cardiac maturation.
O'Hern et al.
Traction
Real revenue. Real partners. Already backed.
$8.4M+
Non-dilutive funding to MSU for underlying biology R&D
Worldwide
Exclusive MSU platform license · executed 2026
8
Patent families · 4 tissue + 4 AI/data
4 delivered
Commercial partners · 1 acquired
Delivered4 commercial partners (1 acquired)
In pilot3 commercial partners, including a pharma partner
In discussion6 big pharma partners, 4 CROs
Commercial demand is outpacing our current capacity.
The people
Built cell therapies before. Doing it again with AI/ML and Smart Manufacturing.
A compact executive team engineers biology, analytics, and process, while advisors and consultants accelerate commercial launch, manufacturing, and translational validation.
Rajib Biswas, PhD
CEO & Co-founder
Led cardiac cell therapy at Sana and technical evaluation at Resilience; UW Heart Regeneration Program and Stanford GSB.
